Patents asserted against Janssen Biotech, Inc. & Genmab in the United States have been declared invalid by summary judg­ment

Copenhagen, Denmark (Press Release) – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that the U.S. District Court of Delaware has declared the three U.S. patents (Nos. 8,263,746, 9,200,061, and 9,758,590), asserted by MorphoSys AG against Genmab and Genmab’s col­lab­o­ration partner Janssen Biotech, Inc. (Janssen) are invalid by summary judg­ment. The patent infringement lawsuit was ini­ti­ated by MorphoSys against Genmab and Janssen in April 2016 asserting that activ­i­ties with DARZALEX (dara­tu­mu­mab) in the United States infringe its U.S. patents, and the case has been pend­ing before the U.S. District Court of Delaware. The …

Planegg / Munich, Germany (Press Release) – MorphoSys AG (FSE: MOR; Prime Standard Seg­ment, MDAX & TecDAX; NASDAQ: MOR) announces that it was informed today that in its lawsuit against Janssen Biotech and Genmab A/S, the United States (U.S.) District Court of Delaware, based on a hearing held No­vem­ber 27, 2018, has ruled in a Court Order on Jan­u­ary­ 25, 2019, that the asserted claims of three MorphoSys patents with U.S. Patent Numbers 8,263,746; 9,200,061 and 9,758,590 are invalid. The Court thus granted a motion for Summary Judgement of invalidity filed by Janssen Biotech …

Patent covers composition of mat­ter and use in solid and liquid tumor cancer indi­ca­tions

Florham Park, NJ (Press Release) – Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the discovery, devel­op­ment and com­mer­cial­iza­tion of targeted treat­ments for cancer, an­nounces that the Japan Patent Office has granted the pat­ent titled “Phos­pho­lipid Analogs as Diapeutic Agents and Methods of Use Thereof” with appli­ca­tion num­ber 2016135920. The pat­ent provides composition of mat­ter and use pro­tec­tion for the com­pany’s pro­pri­e­tary phos­pho­lipid ether (PLE) analogs and spe­cif­i­cally CLR 131 in breast, brain, leukemias and a variety of other cancers.

“Certain cancers such as pedi­atric lym­phomas and leukemias have a …

Berkeley, CA (Press Release) – Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that the United States Patent and Trademark Office has issued a new composition of matter patent related to altered APRIL-binding anti­bodies, further enhancing the com­pany’s B-select intellectual property port­folio. Specifically, the granted claims cover BION-1301, Aduro’s first-in-class anti-APRIL anti­body being eval­u­ated in a Phase 1/2 dose escalation trial for the treat­ment of multiple myeloma.

“Blocking APRIL rep­re­sents a unique ap­proach to treating patients with multiple myeloma and we believe BION-1301 has poten­tial to treat a myriad of on­col­ogy indi­ca­tions as …

Madison, WI (Press Release) – Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the discovery, devel­op­ment and com­mer­cial­iza­tion of targeted treat­ments for can­cer, an­nounces that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. P150207US03, entitled “Alkylphosphocholine analogs for mul­ti­ple myeloma imaging and ther­apy.” The claims in this pat­ent cover a method of use for CLR 131, the com­pany's pro­pri­e­tary lead Phospholipid Drug Conjugate™ (PDC™) in mul­ti­ple myeloma (MM). Cellectar and the Wisconsin Alumni Research Foundation (WARF) are joint owners of the pat­ent and Cellectar has licensed …

Covers composition of mat­ter and method of use for pro­pri­e­tary PDCs™ in com­bi­na­tion with anti-cancer agents

Madison, WI (Press Release) – Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the discovery, de­vel­op­ment and com­mer­cial­i­za­tion of targeted treat­ments for cancer, an­nounces that the U.S. Patent and Trademark Office (USPTO) has granted pat­ent num­ber 9,345,718, titled “Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles,” re­lated to the com­pany’s phos­pho­lipid-ether analogs for targeting anticancer thera­peutics to tumors and cancer stem cells.

“This seminal pat­ent provides Cellectar with broad pro­tec­tion for Phospholipid Drug Conjugate™ (PDC™) prod­ucts created with our phos­pho­lipid ether tech­nology, as well as the freedom to op­er­ate that is nec­es­sary to …

Planegg / Munich, Germany (Press Release) – MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced that it has added a second patent with US Patent Number 9,200,061 to its lawsuit against Janssen Biotech, and Genmab, A/S. This patent claims methods of treating hema­to­logic cancer asso­ci­ated with the undesired presence of CD38-positive cells by admin­istering anti­bodies that bind to a specific region of the target molecule, CD38. In a hearing that took place on Feb­ru­ary 6, 2017 the District Court granted MorphoSys's request to add the 9,200,061 patent to the …